We are live on ! Find out more
IGC icon

IGC Pharma

25 hedge funds and large institutions have $943K invested in IGC Pharma in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more capital invested

Capital invested by funds: $691K → $943K (+$252K)

0% more funds holding

Funds holding: 2525 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

0.3% less ownership

Funds ownership: 3.87%3.57% (-0.3%)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

Holders
25
Holders Change
Holders Change %
0%
% of All Funds
0.36%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
2
Reduced
5
Closed
6
Calls
Puts
Net Calls
Net Calls Change

IGC Hedge Fund Activity: Q1 2024 in Review

25 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q1 2024, worth a combined $943K — up 36% from $691K a quarter earlier.

Fund positioning in IGC was balanced in Q1 2024: 6 funds opened new positions, 6 closed out, 2 added to existing stakes and 5 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $43.9K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $21.5K sold.

  • 25 institutional investors held IGC Pharma (IGC) as of Q1 2024, unchanged from Q4 2023.
  • Funds reported $943K of IGC Pharma stock for Q1 2024, up 36% quarter-over-quarter.
  • 6 funds opened new IGC Pharma positions in Q1 2024 and 6 closed out, a net change of 0 holders.
  • The largest IGC Pharma buyer in Q1 2024 was Renaissance Technologies, an estimated $43.9K added.
  • The largest IGC Pharma seller in Q1 2024 was Susquehanna International Group, an estimated $21.5K sold.

Based on aggregated 13F filings for Q1 2024.